|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 3386541 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16818985.0 |
| Date of filing the European patent application | 2016-12-05 | |
| (97) | Date of publication of the European application | 2018-10-17 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-08 |
| (46) | Date of publication of the claims translation | 2020-10-26 |
| (86) | Number | PCT/EP2016/002040 |
| Date | 2016-12-05 |
| (87) | Number | WO 2017/097407 |
| Date | 2017-06-15 |
| (30) | Number | Date | Country code |
| 15198233 | 2015-12-07 | EP |
| (72) |
RINALDI, Gianluca, IT
DEL RIO, Alessandra, IT
FRATARCANGELI, Silvia, IT
VOSS, Senta, DE
WEIGANDT, Markus, DE
|
| (73) |
Merck Patent GmbH,
Frankfurter Strasse 250, 64293 Darmstadt,
DE
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Vandeninė farmacinė kompozicija, apimanti anti-PD-1 antikūną avelumabą |
| AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-1 ANTIBODY AVELUMAB |
| Payment date | Validity (years) | Amount | |
| 2025-11-19 | 10 | 231.00 EUR |
| 2026-12-05 |